MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to creating precision treatments for debilitating central nervous system (CNS) disorders. The company's proprietary discovery platform combines optogenetics, transcriptomics, and STARmap technologies to identify specific neural circuits causally linked to brain disorders, allowing for highly targeted therapeutic modulation. MapLight's lead product candidate, ML-007C-MA, is a fixed-dose combination muscarinic agonist advancing through Phase 2 clinical trials for the treatment of schizophrenia and Alzheimer's disease psychosis. The company is also developing ML-004, which is in Phase 2 trials for autism spectrum disorder, alongside preclinical programs for Parkinson's disease. Headquartered in Redwood City, California, MapLight aims to establish a new standard of care by moving beyond traditional, broad-acting CNS treatments to circuit-specific pharmacotherapies.
